Novo Nordisk Shares Plunge Amid Sales Outlook

Novo Nordisk Shares Plunge Amid Sales Outlook

Novo Nordisk, a leading Danish drugmaker, revealed that its U.S. sales and profit are expected to decline in 2026 due to pricing pressures and loss of exclusivity for key drugs like Wegovy and Ozempic in major markets. The company's shares fell 14% after the announcement, reflecting investor concerns about its competitive position in the weight-loss drug market.

The company is banking on its oral Wegovy pill launch in the U.S. and strategic moves to expand its market reach, despite facing stiff competition from Eli Lilly's Mounjaro and Zepbound. Novo Nordisk aims to mitigate declining sales by increasing patient access and enhancing product offerings.